Latest Breaking News On - Patients with multiple - Page 9 : vimarsana.com

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

RAHWAY, N.J. (BUSINESS WIRE) Oct 13, 2023

United statesPeter dannenbaumJulie cunninghamDamini chokshiMichael mcardleEuropean commissionMerck co incStatement of merck co incEuropean unionMerck research laboratoriesExchange commissionEuropean medicines agencyMedicinal productsHuman useCombined positive scoreMarjorie green

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumJulie cunninghamDamini chokshiExchange commissionAmerican society of clinical oncologyDrug administrationMerck research laboratoriesStatement of merck co incEuropean society for medical oncologyMerck co incEuropean societyMedical oncologyMarjorie greenMerck researchClinical oncology

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

First Phase 3 survival data from KEYNOTE-A39/EV-302 support potential benefit of combination approach in previously untreated locally advanced or metastatic urothelial cancer; data are selected for.

United statesSeagen padcevSeagen incEuropean society for medical oncologyAgensys incMerck research laboratoriesMerck co incExchange commissionStatement of merck co incEuropean societyMedical oncologyMarjorie greenMerck researchOncology investor eventProffered paperBacillus calmette guerin unresponsive

Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

Merck s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPeter dannenbaumDamini chokshiJulie cunninghamChrissy trankAlliance for clinical trials in oncologyNational clinical trials network groupsNational institutes of healthUs national cancer instituteDevelopment agreementExchange commissionData monitoring committeeStatement of merck co incMerck research laboratoriesMerck co incMarjorie green

Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery

Merck (MRK) KEYTRUDA Met Primary Endpoint of DFS in Certain Patients With MIUC After Surgery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMerck research laboratoriesNational institutes of healthDevelopment agreementNational clinical trials network groupsAlliance for clinical trials in oncologyUs national cancer instituteData monitoring committeeMarjorie greenMerck researchCancer instituteNational institutesClinical trialsNational clinical trials networkCooperative researchBacillus calmette guerin unresponsive